1.
|
Phase: Phase IV Type: Treatment Status: Active Age: 21 and under Sponsor: Other Protocol IDs: SCT 0208, NCT00679536
|
|
2.
|
Phase: Phase III Type: Supportive care, Treatment Status: Active Age: 1 to < 10 Sponsor: NCI, Other Protocol IDs: CDR0000683227, COG-AALL0932, AALL0932, NCT01190930
|
|
3.
|
Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 1 to 30 Sponsor: NCI, Other Protocol IDs: CDR0000706370, COG-AALL1131, AALL1131, NCT01406756
|
|
4.
|
Phase: Phase II Type: Treatment Status: Active Age: 1 to 21 Sponsor: Pharmaceutical / Industry Protocol IDs: CA180-226, 2008-002260-33, NCT00777036
|
|
5.
|
Phase: Phase II Type: Treatment Status: Active Age: Under 60 Sponsor: Other Protocol IDs: 2008-0363, NCT00857389
|
|
6.
|
Phase: Phase II Type: Treatment Status: Active Age: 8 to 75 Sponsor: NHLBI Protocol IDs: 090087, 09-H-0087, NCT00859586
|
|
7.
|
Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 0 to 65 Sponsor: Other Protocol IDs: 2009-0209, NCT00990249
|
|
8.
|
Phase: Phase II Type: Treatment Status: Active Age: 1 to 17 Sponsor: Pharmaceutical / Industry Protocol IDs: CA180-372, 2011-001123-20, AALL1122, NCT01460160
|
|
9.
|
Phase: Phase I Type: Treatment Status: Active Age: 50 and under Sponsor: NCI, Other Protocol IDs: CDR0000491633, DFCI-05030, MDA-2005-0695, NCT00376480
|
|
10.
|
Phase: Phase I Type: Treatment Status: Active Age: 1 to 80 Sponsor: Other Protocol IDs: 2010-0658, NCT01471067
|